Anti-CD20 therapies in pregnancy and breast feeding : a review and ABN guidelines
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ..
Neurologists increasingly use anti-CD20 therapies, including for women of childbearing age, despite these medications being unlicensed for use in pregnancy. Current evidence suggests that women can safely conceive while taking anti-CD20 therapy. Women should not be denied treatment during pregnancy when it is clinically indicated, although they should be counselled regarding live vaccinations for their infant. Women receiving regular ocrelizumab for multiple sclerosis should preferably wait 3 months before trying to conceive. There are few data around ofatumumab in pregnancy, and while there is probably a class effect across all anti-CD20 therapies, ofatumumab may need to be continued during pregnancy to maintain efficacy. We recommend that anti-CD20 therapies can be safely given while breast feeding. It is important to make time to discuss treatments with women of childbearing age to help them choose their most suitable treatment. Outcomes should be monitored in pregnancy registries.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Practical neurology - 23(2023), 1 vom: 08. Feb., Seite 6-14 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dobson, Ruth [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 01.02.2023 Date Revised 02.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/pn-2022-003426 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343242427 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343242427 | ||
| 003 | DE-627 | ||
| 005 | 20231226015957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/pn-2022-003426 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1144.xml |
| 035 | |a (DE-627)NLM343242427 | ||
| 035 | |a (NLM)35803727 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dobson, Ruth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-CD20 therapies in pregnancy and breast feeding |b a review and ABN guidelines |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2023 | ||
| 500 | |a Date Revised 02.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a Neurologists increasingly use anti-CD20 therapies, including for women of childbearing age, despite these medications being unlicensed for use in pregnancy. Current evidence suggests that women can safely conceive while taking anti-CD20 therapy. Women should not be denied treatment during pregnancy when it is clinically indicated, although they should be counselled regarding live vaccinations for their infant. Women receiving regular ocrelizumab for multiple sclerosis should preferably wait 3 months before trying to conceive. There are few data around ofatumumab in pregnancy, and while there is probably a class effect across all anti-CD20 therapies, ofatumumab may need to be continued during pregnancy to maintain efficacy. We recommend that anti-CD20 therapies can be safely given while breast feeding. It is important to make time to discuss treatments with women of childbearing age to help them choose their most suitable treatment. Outcomes should be monitored in pregnancy registries | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a MULTIPLE SCLEROSIS | |
| 650 | 7 | |a Antigens, CD20 |2 NLM | |
| 700 | 1 | |a Rog, David |e verfasserin |4 aut | |
| 700 | 1 | |a Ovadia, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Murray, Katy |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Stella |e verfasserin |4 aut | |
| 700 | 1 | |a Ford, Helen L |e verfasserin |4 aut | |
| 700 | 1 | |a Pearson, Owen R |e verfasserin |4 aut | |
| 700 | 1 | |a White, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Bonham, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Mathews, Joela |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson-Piercy, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Brex, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Practical neurology |d 2007 |g 23(2023), 1 vom: 08. Feb., Seite 6-14 |w (DE-627)NLM169632148 |x 1474-7766 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:08 |g month:02 |g pages:6-14 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/pn-2022-003426 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 08 |c 02 |h 6-14 | ||